Vaishali Pharma Ltd. (IN:VAISHALI)
:VAISHALI
VAISHALI Stock Chart & Stats
₹8.04
-₹0.33(-1.95%)
At close: 4:00 PM EST
₹8.04
-₹0.33(-1.95%)
Day’s Range― - ―
52-Week Range₹4.75 - ₹15.24
Previous CloseN/A
Volume565.66K
Average Volume (3M)399.32K
Market Cap
₹641.01M
Enterprise Value₹779.06M
Total Cash (Recent Filing)₹10.46M
Total Debt (Recent Filing)₹156.01M
Price to Earnings (P/E)21.3
Beta1.23
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding107,192,130
10 Day Avg. Volume443,817
30 Day Avg. Volume399,324
Financial Highlights & Ratios
PEG Ratio-11.89
Price to Book (P/B)0.26
Price to Sales (P/S)0.17
P/FCF Ratio-0.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained ~15% revenue growth indicates durable demand for the company’s products and expanding market penetration. Over a 2–6 month horizon this growth supports scale benefits, improves fixed-cost absorption, and provides a foundation to restore margins if cost headwinds are managed.
Healthy Equity BaseA stable balance sheet with a healthy shareholders’ equity position and moderate debt-to-equity provides financial flexibility. This reduces near-term refinancing risk, enables funding for working capital or targeted investments, and supports resilience through operational recoveries.
Positive Net Profit MarginMaintaining a positive net margin despite operating pressures suggests some non-operating offsets or tax/one-off dynamics that preserve bottom-line earnings. This provides a cushion for retained earnings and supports solvency while management works to restore operating profitability.
Bears Say
Negative Operating Cash FlowMaterial negative operating and free cash flow erode internal funding ability, forcing reliance on external financing or equity to fund capex and working capital. Over months this weakens financial flexibility, raises liquidity risk, and constrains capacity for R&D or commercial expansion.
Operating Profitability PressureA negative EBIT and declining gross margin point to structural cost pressures or pricing erosion. Persistent operating losses undermine reinvestment capacity and make earnings recovery dependent on meaningful cost or pricing improvements, which can take several quarters to realize.
Earnings Per Share DeclineNegative EPS growth signals deteriorating underlying profitability per share and may reflect margin compression or dilution. Over the medium term, declining EPS reduces retained earnings growth and could limit the company’s ability to fund projects internally or restore investor confidence.
Vaishali Pharma Ltd. News
VAISHALI FAQ
What was Vaishali Pharma Ltd.’s price range in the past 12 months?
Vaishali Pharma Ltd. lowest stock price was ₹4.75 and its highest was ₹15.24 in the past 12 months.
What is Vaishali Pharma Ltd.’s market cap?
Vaishali Pharma Ltd.’s market cap is ₹641.01M.
When is Vaishali Pharma Ltd.’s upcoming earnings report date?
Vaishali Pharma Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 57 days.
How were Vaishali Pharma Ltd.’s earnings last quarter?
Vaishali Pharma Ltd. released its earnings results on Feb 13, 2026. The company reported ₹0.101 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.101.
Is Vaishali Pharma Ltd. overvalued?
According to Wall Street analysts Vaishali Pharma Ltd.’s price is currently Overvalued.
Does Vaishali Pharma Ltd. pay dividends?
Vaishali Pharma Ltd. does not currently pay dividends.
What is Vaishali Pharma Ltd.’s EPS estimate?
Vaishali Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaishali Pharma Ltd. have?
Vaishali Pharma Ltd. has 107,192,130 shares outstanding.
What happened to Vaishali Pharma Ltd.’s price movement after its last earnings report?
Vaishali Pharma Ltd. reported an EPS of ₹0.101 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.126%.
Which hedge fund is a major shareholder of Vaishali Pharma Ltd.?
Currently, no hedge funds are holding shares in IN:VAISHALI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaishali Pharma Ltd.
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti-platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti-malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, anti-fungal, anti-inflammatory/analgesic/anti-pyretic, anti-diabetic, cardiac, vitamins, topical steroids/corticosteroids, and other formulations. In addition, it offers veterinary pharmaceutical, nutraceutical, oncology, herbal, and surgical products. The company was founded in 1989 and is headquartered in Mumbai, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Bafna Pharmaceuticals Limited
―
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Krebs Biochemicals & Industries Ltd.
―